Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 18 MAY 2001

Electronic Filings

Hughes & Luce LLP
Explore more from Hughes & Luce LLP

United StatesCorporate/Commercial Law

On October 27, 2000, the U.S. Patent and Trademark Office initiated full implementation of its Electronic Patent application filing System (EFS). EFS allows anyone to file an application for a new invention with the USPTO by using the Internet. The use of EFS is completely voluntary for new utility patent applications filings. EFS allows utility applications to be filed 24 hours a day, seven days a week. Applicants immediately receive an electronic Acknowledgement Receipt upon a successful filing that includes a USPTO assigned application serial number and a date. This receipt is by electronic "postcard." Any electronic submission is automatically validated for completeness against USPTO business rules, thus saving time and effort caused by filing of incomplete applications.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP